MYO1D

Across TCGA pan-cancer cohorts, MYO1D RNA is linked to patient survival in 24 of 34 cancer types, making it the most broadly survival-associated MYO1D data layer compared with 6 for mutation status and 6 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher MYO1D RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MYO1D expression acts as an unfavorable survival marker, although some lineages such as KIRC and READ show a favorable association.

BLCA, KIRC, and READ are the cancer types where MYO1D RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Quartile	All	0.290	0.520	<.001	92	view →
KIRC	DFS	Quartile	All	0.739	0.543	<.001	62	view →
READ	OS	Median	II,III,IV	1.000	0.800	.003	38	view →
SKCM	OS	Quartile	All	0.244	0.410	.001	33	view →
UCEC	DFS	Quartile	All	0.541	0.753	.003	28	view →
LUAD	OS	Quartile	III,IV	0.437	0.751	.017	27	view →
BRCA	OS	Tertile	II,III,IV	0.502	0.727	.001	21	view →
ACC	OS	Tertile	IV	0.253	0.886	.024	21	view →
MESO	DFS	Median	III,IV	0.285	0.539	<.001	21	view →
LUSC	OS	Median	All	0.622	0.726	.004	18	view →
COAD	OS	Tertile	IV	0.719	0.363	.012	12	view →
GBM	OS	Quartile	All	0.303	0.512	.006	11	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 24 lineages.

MYO1D–BLCA (OS)

Open the BLCA breakdown →